Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Receivables: 2023-2025

Historic Receivables for Iovance Biotherapeutics (IOVA) over the last 2 years, with Sep 2025 value amounting to $66.8 million.

  • Iovance Biotherapeutics' Receivables rose 19.71% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.0 million, marking a year-over-year increase of 204.22%. This contributed to the annual value of $69.3 million for FY2024, which is 45820.53% up from last year.
  • Iovance Biotherapeutics' Receivables amounted to $66.8 million in Q3 2025, which was up 11.38% from $59.9 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Receivables peaked at $70.9 million during Q1 2025, and registered a low of $33,000 during Q2 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Receivables value was $55.8 million (recorded in 2024), while the average stood at $39.4 million.
  • Data for Iovance Biotherapeutics' Receivables shows a peak YoY surged of 95,669.70% (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Receivables (Quarterly) stood at $151,000 in 2023, then spiked by 45,820.53% to $69.3 million in 2024, then climbed by 19.71% to $66.8 million in 2025.
  • Its last three reported values are $66.8 million in Q3 2025, $59.9 million for Q2 2025, and $70.9 million during Q1 2025.